EuroPCR Late-Breaking Clinical Trial Data Finds Effectiveness of Elixir Medical's DynamX Bioadaptor for PCI Treatment

Late-breaking clinical data presented at EuroPCR 2023 in Paris demonstrated Elixir Medical’s DynamX Bioadaptor restores vessel motion and function with better effectiveness at 12 months compared to a leading drug-eluting stent (DES).

Related Keywords

California ,United States ,Paris ,France General ,France ,Milpitas ,Motasim Sirhan ,Development Of The Dynamx Bioadaptor ,Elixir Medical Corporation ,Elixir Medical ,Dynamx Coronary Drug Eluting Bioadaptor ,Resolute Onyx Drug Eluting Stent ,Target Lesion Failure ,Resolute Onyx ,Dynamx Bioadaptor ,Clinical Safety ,Dynamx Coronary Bioadaptor System ,